Industry News

The move expands early-phase bioconjugates development and manufacturing capabilities at its Oss, Netherlands site.

The 300,000-square-foot site in Richfield adds cleanroom capacity and 300 jobs to support high-volume pharmaceutical device manufacturing.

The CDMO’s Leganés facility expansion adds clinical and pilot-scale capacity for potent oral solid dose programs.

The collaboration supports clinical production and regulatory work for a CRISPR-edited GD2 CAR-T program targeting solid tumors.

The new facility, part of J&J’s previously announced $55 billion U.S. investment, will expand domestic capacity and support its pipeline of advanced treatments.

The expansion is intended to add on-site commercial freeze-drying to support payload and linker manufacturing by early 2027.

The new facility in Sudair will serve as the company’s regional production hub for the Middle East and North Africa.

The deal pairs early-stage active pharmaceutical ingredient capabilities in Israel with Recipharm’s global late-stage and commercial manufacturing network.

The program will integrate AI-driven robotics into GMP cell therapy workflows to improve cycle times, durability, and scalability, according to the companies.

The new Shanghai facility will support commercialization and future allogeneic CAR T production.

The financing will support the commercial rollout of scalable nanoparticle manufacturing platforms for advanced therapeutics.

The facility in Suzhou, China, which also passed an EU audit in 2024, will support commercial production of the dengue vaccine for Brazil.

The partnership links early formulation and clinical supply with late-stage scale-up and commercial manufacturing.

The digital collaboration links clinical trial, registry, and medical record data to support study design and faster evidence generation.

The partnership links academic research with an integrated discovery platform to move programs toward clinical development.

The five-year plan includes local production and clinical R&D collaboration designed to strengthen pandemic preparedness in the country.

The $46 million investment targets U.S. manufacturing capacity for ropeginterferon alfa-2b used to treat polycythemia vera in adults.

The collaboration aims to onshore active pharmaceutical ingredient and finished dose production for the essential medicine used in hospitals nationwide.

The alliance looks to achieve shorter vein-to-vein timelines for cell and gene therapy and lower production costs.

The pharmaceutical company’s new lipid-based microbubble technology targets upstream cell selection and activation steps.

The collaboration with the National Research Council of Canada and Daresbury Proteins aims to target higher-yield expression systems to streamline conjugate production.

The CDMO will provide access to up to 50 million vaccine doses during a future pandemic.

The agreement covers a preclinical trispecific candidate for B-cell mediated autoimmune diseases.

Manufacturing is expected to begin in 2026 at OXB’s sites in Oxford, UK, and Durham, North Carolina.

The transaction provides infrastructure to broaden Nanologica’s product portfolio beyond silica-based purification media, according to the announcement.

The CDMO completed development, scale-up, and commercialization of the delivery system across two sites within five months.

The authorization for the U.S.-headquartered CDMO allows biologics and biosimilars made at the site to be commercialized in the South American country.

The collaboration expands automated cell therapy manufacturing beyond T cells into hematopoietic stem cells.

Manufacturing of ExpreS2ion Biotechnologies’ Nipah vaccine program is scheduled to begin in the first quarter of 2026 under an EU-funded development program.

The tool is designed to reduce the time and resources required to convert paper batch records into digital workflows, according to the company.